NNovo Nordisk Read More Novo Nordisk Juggles Share Buybacks and Pipeline Hype as CagriSema Data Approaches2026-06-01 Danish pharma giant unveils REIMAGINE Phase 3 results for CagriSema, runs $1.6B buyback, as stock tumbles 39% amid…